Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03583164 · ClinicalTrials.gov registry record · Phase 2
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
A Phase 2 study, sponsored by F2G Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT03583164 is a Phase 2 study that has completed, run by F2G Biotech. The registered enrollment target is 203 participants.
The verdict
NCT03583164, a Phase 2 study, has completed, sponsored by F2G Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in participants lacking suitable alternative treatment options.
Interventions
- DRUG Olorofim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03583164
The ClinicalTrials.gov registry entry for NCT03583164 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is F2G Biotech, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olorofim is the first listed.
NCT03583164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03583164 about?
NCT03583164 is a clinical study titled "Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options". A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in participants lacking suitable alternative treatment options.
What is the current status of trial NCT03583164?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2018-06-06. Estimated completion is 2023-02-10.
What interventions are being tested in trial NCT03583164?
The interventions under investigation include: Olorofim (DRUG).
Who is sponsoring clinical trial NCT03583164?
This trial is sponsored by F2G Biotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.